SLNSW-Neoadjuvant pyrotinib, trastuzumab, and docetaxel...-TN_cdi_doaj_primary_oai_doaj_org_article_d032fcc84aa544e0b0ed2042112d1d40

Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial

Full title: Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial

Author/creator: Wu, Jiong, Jiang, Zefei, Liu, Zhenzhen, Yang, Benlong, Yang, Hongjian, Tang, Jinhai, Wang, Kun, Liu, Yunjiang, Wang, Haibo, Fu, Peifen, Zhang, Shuqun, Liu, Qiang, Wang, Shusen, Huang, Jian, Wang, Chuan, Wang, Shu, Wang, Yongsheng, Zhen, Linlin, Zhu, Xiaoyu, Wu, Fei, Lin, Xiang, Zou, Jianjun.

Call Numbers:

Record Identifier: TN_cdi_doaj_primary_oai_doaj_org_article_d032fcc84aa544e0b0ed2042112d1d40

Language: English

Formats: Articles

Publishers: England: BioMed Central Ltd

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d032fcc84aa544e0b0ed2042112d1d40

Articles

Articles

Export this record

Export selected records

  • Export to excel
  • Permalink

    • Export record to excel

    File type to download

    Beta version

    Record title

    Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial

    Record identifier

    TN_cdi_doaj_primary_oai_doaj_org_article_d032fcc84aa544e0b0ed2042112d1d40

    Record permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d032fcc84aa544e0b0ed2042112d1d40

    Share

    Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial

    ACCESS
    https://collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d032fcc84aa544e0b0ed2042112d1d40

    Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial

    Full title

    Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial

    Author / Creator

    Wu, Jiong ; Jiang, Zefei ; Liu, Zhenzhen ; Yang, Benlong ; Yang, Hongjian ; Tang, Jinhai ; Wang, Kun ; Liu, Yunjiang ; Wang, Haibo ; Fu, Peifen ; Zhang, Shuqun ; Liu, Qiang ; Wang, Shusen ; Huang, Jian ; Wang, Chuan ; Wang, Shu ; Wang, Yongsheng ; Zhen, Linlin ; Zhu, Xiaoyu ; Wu, Fei ; Lin, Xiang ; Zou, Jianjun

    Publisher

    England: BioMed Central Ltd

    Journal title

    BMC medicine, 2022, Vol.20 (1), p.498-10

    Record Identifier

    TN_cdi_doaj_primary_oai_doaj_org_article_d032fcc84aa544e0b0ed2042112d1d40

    Language

    English

    Formats

    Articles

    Publication information

    Publisher

    Subjects

    Subjects and topics

    Antibodies, Monoclonal, Humanized - adverse effects Antineoplastic Combined Chemotherapy Protocols - adverse effects Breast cancer Breast Neoplasms - pathology Docetaxel Docetaxel - therapeutic use Dosage and administration Female HER2 Humans Neoadjuvant therapy Neoadjuvant Therapy - adverse effects Neoadjuvant treatment Phase 3 Pyrotinib Receptor, ErbB-2 - genetics Testing Trastuzumab Treatment Outcome

    More information

    — SCOPE AND CONTENTS

    Contents

    — ALTERNATIVE TITLES

    Full title

    — AUTHORS, ARTISTS AND CONTRIBUTORS

    Author / Creator

    Identifiers

    — PRIMARY IDENTIFIERS

    Record Identifier

    TN_cdi_doaj_primary_oai_doaj_org_article_d032fcc84aa544e0b0ed2042112d1d40

    Permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d032fcc84aa544e0b0ed2042112d1d40

    — OTHER IDENTIFIERS

    ISSN

    E-ISSN

    DOI

    How to access this item

    Online

    1 item

    How to access?

    Login with a Library card

    Full text available >

    About resource >

    View in old catalogue

    Connecting people and collections